Edition:
United States

ContraVir Pharmaceuticals Inc (CTRV.OQ)

CTRV.OQ on NASDAQ Stock Exchange Capital Market

0.94USD
4:00pm EDT
Change (% chg)

$-0.10 (-9.21%)
Prev Close
$1.04
Open
$1.05
Day's High
$1.05
Day's Low
$0.94
Volume
46,361
Avg. Vol
22,071
52-wk High
$6.56
52-wk Low
$0.94

Select another date:

Fri, May 18 2018

BRIEF-Contravir Pharma Files For Series C Convertible Preferred Stock

* CONTRAVIR PHARMACEUTICALS FILES FOR SERIES C CONVERTIBLE PREFERRED STOCK AND WARRANTS TO PURCHASE SHARES OF COMMON STOCK OF UP TO $20 MILLION - SEC FILING Source text: (https://bit.ly/2wUNyv5) Further company coverage:

BRIEF-Contravir Pharmaceuticals Says Stockholders Approved Reverse Stock Split Of Common Stock

* CONTRAVIR PHARMACEUTICALS SAYS STOCKHOLDERS APPROVED REVERSE STOCK SPLIT OF COMMON STOCK AT RATIO WITHIN RANGE OF 1-FOR-5 AND 1-FOR-20 - SEC FILING Source text : [http://bit.ly/2p2XwU7] Further company coverage:

BRIEF-Contravir's TXL Granted Orphan Drug Designation For Treatment Of HBV In Pediatric Population

* CONTRAVIR PHARMACEUTICALS ANNOUNCES TXL™ HAS BEEN GRANTED ORPHAN DRUG DESIGNATION FOR THE TREATMENT OF HBV IN A PEDIATRIC POPULATION Source text for Eikon: Further company coverage:

BRIEF-ContraVir Pharmaceuticals Reaches Agreement With The FDA

* CONTRAVIR PHARMACEUTICALS REACHES AGREEMENT WITH THE FDA ON THE NDA PACKAGE FOR TXL™ LEVERAGING THE 505(B)(2) REGULATORY PATHWAY

BRIEF-Contravir Pharma Completes Renal Impairment Study With TXL

* CONTRAVIR PHARMACEUTICALS COMPLETES RENAL IMPAIRMENT STUDY WITH TXL Source text for Eikon: Further company coverage:

Select another date: